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ABSTRACT Recent work demonstrated that the Niemann-Pick C1 (NPC1) protein is an essential entry receptor for filoviruses.
While previous studies focused on filovirus entry requirements of NPC1 in vitro, its roles in filovirus replication and pathogene-
sis in vivo remain unclear. Here, we evaluated the importance of NPC1, and its partner in cholesterol transport, NPC2, by using
a mouse model of Ebolavirus (EBOV) disease. We found that, whereas wild-type mice had high viral loads and succumbed to
EBOV infection,Npc1/mice were entirely free of viral replication and completely protected from EBOV disease. Interestingly,
Npc1/mice transiently developed high levels of viremia, but were nevertheless substantially protected from EBOV challenge.
We also foundNpc2/mice to be fully susceptible to EBOV infection, whileNpc1/mice treated to deplete stored lysosomal
cholesterol remained completely resistant to EBOV infection. These results provide mechanistic evidence that NPC1 is directly
required for EBOV infection in vivo, with little or no role for NPC1/NPC2-dependent cholesterol transport. Finally, we assessed
the in vivo antiviral efficacies of three compounds known to inhibit NPC1 function or NPC1-glycoprotein binding in vitro. Two
compounds reduced viral titers in vivo and provided a modest, albeit not statistically significant, degree of protection. Taken
together, our results show that NPC1 is critical for replication and pathogenesis in animals and is a bona fide target for develop-
ment of antifilovirus therapeutics. Additionally, our findings withNpc1/mice raise the possibility that individuals heterozy-
gous for NPC1may have a survival advantage in the face of EBOV infection.
IMPORTANCE Researchers have been searching for an essential filovirus receptor for decades, and numerous candidate receptors
have been proposed. However, none of the proposed candidate receptors has proven essential in all in vitro scenarios, nor have
they proven essential when evaluated using animal models. In this report, we provide the first example of a knockout mouse that
is completely refractory to EBOV infection, replication, and disease. The findings detailed here provide the first critical in vivo
data illustrating the absolute requirement of NPC1 for filovirus infection in mice. Our work establishes NPC1 as a legitimate
target for the development of anti-EBOV therapeutics. However, the limited success of available NPC1 inhibitors to protect mice
from EBOV challenge highlights the need for newmolecules or approaches to target NPC1 in vivo.
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Filoviruses, members of the family Filoviridae of nonsegmentednegative-strand RNA viruses, cause sporadic viral hemor-
rhagic fever outbreaks that primarily affect areas of equatorial
Africa (1). Five filoviruses are currently associated with severe dis-
ease in humans: Ebola virus (EBOV; formerly termed Zaire ebo-
lavirus), Bundibugyo virus (BDBV), Sudan virus (SUDV), Mar-
burg virus (MARV), and Ravn virus (RAVV) (2). Filovirus virions
are enveloped filamentous particles with a uniform diameter of
80 nm and variable lengths. A single transmembrane glycoprotein
(GP), consisting of two subunits (GP1 and GP2) and organized
into trimeric spikes on the virion surface, mediates viral entry into
cells (3, 4). Filovirus virions bind to host cells via several reported
attachment proteins (5–8) and are then internalized and delivered
to the endosomal pathway (9–11). In late endosomes, host cys-
teine proteases cleave and remove large C-terminal regions of the
GP1 subunit (the mucin domain and glycan cap), thereby un-
masking a binding site for the cholesterol transport protein
Niemann-Pick C1 (NPC1). NPC1 was recently shown to be an
essential host factor (12, 13) and endosomal/lysosomal entry re-
ceptor (14, 15) for filoviruses.
NPC1 is a large 13-pass transmembrane protein found in the
limiting membrane of late endosomes and lysosomes in all cells
(16). According to the current model, NPC1 is proposed to work
in cooperation with a small soluble lysosomal protein, Niemann-
Pick C2 (NPC2), to mediate transport of luminal cholesterol
across the endosomal/lysosomal membrane for dispersal to other
cellular compartments (17, 18). Loss-of-function mutations in
NPC1 or NPC2 cause a rare and often fatal hereditary neurovis-
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ceral disorder in humans (19, 20).Over time,NPCdisease patients
accumulate cholesterol and glycosphingolipids in various tissues
and organs, leading to neurological dysfunction and organ failure.
U18666a, an amphipathic steroid, reproduces some features of
NPC disease at the cellular level, at least in part by disrupting
NPC1 function (21–24). A direct interaction between NPC1 and
U18666A is proposed to be responsible for U18666A-mediated
lysosomal cholesterol accumulation (23, 25, 26). Imipramine, a
hydrophobic amine and FDA-approved antidepressant, and a va-
riety of other cationic amphiphiles also induce accumulation of
cholesterol and glycosphingolipids in lysosomes and may directly
interfere with NPC1 function (26–28).
Carette et al. used a genetic screen in haploid human cells to
identify NPC1 as a critical host factor for filovirus entry and rep-
lication in vitro (12). They also reported that U18666a and imip-
ramine significantly inhibited filovirus infection by interfering
with viral entry. In a separate chemical screen, Cote et al. identified
an EBOV-specific antiviral compound, 3.47, and attributed its
antiviral activity in cell culture to its ability to block EBOV GP
binding to NPC1-containing membranes (13). Both studies pro-
vided evidence that the cholesterol transport function and GP-
binding function of NPC1 are separable. More recent work
showed that EBOV GP, in its cleaved form, binds directly and
specifically to purified NPC1, that GP directly engages the second
luminal loop of NPC1 (loop C), and that GP-NPC1 binding is
required for filovirus entry and infection in cultured cells (14, 15).
While these recently published efforts clearly illustrate the impor-
tance of NPC1 for filovirus entry in vitro, the importance of NPC1
in vivo is yet to be investigated in detail. Furthermore, NPC1-
targeting compounds have demonstrated potent in vitro antiviral
efficacy against filoviruses, but none has been reported to limit
filovirus replication or pathogenesis in vivo. Here, we provide ev-
idence that Npc1/ mice are completely protected from EBOV
infection and free of replicating virus. We also show that endo-
somal/lysosomal cholesterol accumulation plays little or no role in
murine susceptibility or resistance to EBOV challenge, strongly
implicating the NPC1 protein as a direct mediator of filovirus
infection in vivo. Finally, we demonstrate that compounds that
disrupt NPC1 function in vitro can inhibit viral replication in a
murine model of filovirus pathogenesis.
RESULTS
Npc1/ mice are completely resistant to EBOV pathogenesis
and replication.We previously demonstrated thatNpc1/mice
were highly resistant to mouse-adapted EBOV and mouse-
adaptedMARV inducedmortality, though the animals did display
clinical signs of disease and experienced weight loss (12). Here, we
examined the capacity of EBOV to infectNpc1/mice. We chal-
lenged Npc1/, Npc1/, and wild-type littermate controls in-
traperitoneally (i.p.) with 100 PFU (3,000 50% lethal dose units)
ofmouse-adapted EBOV.Wild-typemice developed clinical signs
of disease, including weight loss (Fig. 1A), ruffled fur, hunched
posture, subdued activity, and severe dehydration, and all suc-
cumbed by day 9 postchallenge (Fig. 1B). As reported previously,
nearly all Npc1/ mice were protected from EBOV infection,
though weight loss and ruffled fur were noted between days 6 and
9 postchallenge. Npc1/ mice were completely protected, with
no clinical signs of disease. Subsets of thesemicewere sacrificed on
days 3 and 7 postchallenge, and tissues were collected to assess
viral titers, histology and immunohistochemistry, and cytokine
expression. Virus was detected in liver, kidney, spleen, and serum
of all tested wild-type and Npc1/ mice euthanized on day 3
postchallenge (Fig. 1C). While viral titers remained elevated in
wild-typemice on day 7, titers were significantly lower inNpc1/
mice euthanized on day 7 (Fig. 1D). No virus was detected in
tissues collected from Npc1/mice at either time point (Fig. 1C
and D).
Histological manifestations within the spleens included lym-
phocytolysis within germinal centers, splenitis, and fibrin accu-
mulation (see Fig. S1 in the supplemental material). Within the
liver, hepatocellular degeneration and necrosis, rare necrotizing
hepatitis, and fibrin accumulation were observed (see Fig. S1).
Overall, no clear distinctions were noted between tissues collected
from wild-type mice and Npc1/ mice on day 3 postchallenge.
Histological abnormalities were more pronounced in the livers of
wild-type mice on day 7 postchallenge than in Npc1/ mice.
Npc1/ mice did not show any notable histological changes in
spleen or liver on either day postchallenge.Within the spleen, cells
morphologically consistent with fibroblastic reticular cells, den-
dritic cells, and macrophages were the predominant cell types an-
tigen positive for EBOV (see Fig. S2 in the supplementalmaterial).
Within the liver, nonparenchymal cells, i.e., hepatic stellate cells
and occasional hepatocytes, were the predominate antigen-
positive cell types (see Fig. S2). No notable differences were ob-
served in spleens or livers collected on day 3 from wild-type or
Npc1/mice. By day 7 postchallenge, antigen-positive cells were
widespread in livers of wild-type mice but remained low (10%)
in Npc1/ mice. Antigen-positive cells in the spleens of both
wild-type andNpc1/mice were equally abundant on day 7. No
EBOV antigen-positive cells were identified in the liver or spleen
ofNpc1/mice on either day postchallenge. No notable changes
were observed in kidneys harvested from any group on either day
postinfection.
EBOV-induced cytokine expression in wild-type and NPC1
knockoutmice.Despite having similar viral loads onday 3 postin-
fection and comparable histological findings, Npc1/mice were
better protected against EBOV infection than their wild-type lit-
termates. To investigate developing immune responses in these
groups, we evaluated cytokine levels in serum collected from
mouse-adapted EBOV infectedNpc1/,Npc1/, and wild-type
littermate controls on days 3 and 7 postinfection. We assessed
proinflammatory cytokines and those critical for coordinating in-
nate immunity. By day 3, tumor necrosis factor alpha (TNF-),
interleukin-6 (IL-6), IL-1, granulocyte-macrophage colony-
stimulating factor (GM-CSF), granulocyte colony-stimulating
factor (G-CSF), and monocyte chemoattractant protein-1
(MCP-1) were elevated in wild-typemice compared to uninfected
control mice (Fig. 2A). On day 7, TNF-, MCP-1, macrophage
inflammatory protein 1 alpha (MIP-1), and regulated on activa-
tion, normal T cell expressed and secreted (RANTES) levels were
significantly elevated in wild-type mice compared to uninfected
mice (Fig. 2B). In Npc1/mice on day 3, significant increases in
TNF-, GM-CSF, and MCP-1 expression were observed com-
pared to uninfected control mice, and IL-1, G-CSF, and MCP-1
levels were significantly lower than in wild-typemice (Fig. 2A). By
day 7, TNF- remained elevated in Npc1/mice relative to un-
infected control mice, and IL-6 and GM-CSF levels were signifi-
cantly higher in Npc1/ mice than in wild-type mice (Fig. 2B).
MIP-1, MCP-1, and RANTES expression was significantly lower
inNpc1/mice than in wild-type mice (Fig. 2B). On both days 3
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(Fig. 2A) and 7 (Fig. 2B), TNF- and GM-CSF were the only
cytokines to be significantly elevated in Npc1/ mice compared
to uninfected controls, while IL-6, IL-1, G-CSF, MIP-1,
MCP-1, and RANTES remained largely unchanged and signifi-
cantly lower than in wild-type mice.
Cytokines important for coordinating adaptive immunity
were also evaluated.Wild-typemice had significantly elevated lev-
els of IL-2, IL-4, IL-5, IL-10, and IL-12p70 on day 3 postchallenge
compared to uninfected control mice (Fig. 2C). By day 7, only
gamma interferon (IFN-) and IL-2 remained elevated in wild-
type mice compared to uninfected controls (Fig. 2D). IL-2, IL-4,
IL-5, IL-10, and IL-12p70 levels were also significantly elevated in
Npc1/ mice relative to levels in uninfected controls on day 3
(Fig. 2C). As in wild-type mice, IL-2 remained elevated in
Npc1/ mice on day 7 compared to uninfected controls. How-
ever, unlike wild-type mice, Npc1/ mice had significantly
higher levels of IL-5 and IL-12p70 than in either uninfected con-
trols or infected wild-type mice (Fig. 2D). IL-10 expression was
also increased in Npc1/ mice relative to uninfected control
mice. On day 3, Npc1/ mice expressed elevated levels of IL-10
and IL-12p70 compared to uninfected control mice. IL-10 and
IL-2 expression levels were significantly lower than in wild-type
mice (Fig. 2C). IL-2 and IFN- levels inNpc/mice were signif-
icantly lower on day 7 compared to levels in wild-type mice
(Fig. 2D).
Lysosomal cholesterol accumulation alone does not confer
resistance to EBOV infection in vivo, and NPC2 is dispensable.
Similar to NPC1 deficiency, NPC2 deficiency causes cholesterol
accumulation in late endosomal/lysosomal compartments of cells
in tissue culture and in vivo (20, 29). To evaluate the role of cho-
lesterol accumulation in resistance to EBOV infection, we chal-
lenged Npc2/, Npc2/, and wild-type littermate controls i.p.
with 100 PFU ofmouse-adapted EBOV andmonitoredmorbidity
and mortality. Despite excess cholesterol accumulation, NPC2-
deficient mice were not protected against lethal EBOV infection
(Fig. 3A and B). All mice developed severe clinical signs of disease,
with all groups experiencing90% mortality.
Recent advances in the field ofNPCdisease research have high-
FIG 1 NPC1 knockout mice are protected frommouse-adapted EBOV infection.Npc1/ (n 28),Npc1/ (n 21), and wild-type littermate control (n
19) mice were challenged i.p. with 100 PFU of mouse-adapted EBOV. Mice were monitored for weight loss (A) and mortality (B) following challenge. On days
3 (C) and 7 (D) postchallenge, subsets of mice from each group were euthanized and viral titers were determined for the indicated tissues by plaque assay. The
dotted line indicates the assay limit of detection. ****, P 0.0001 compared to wild-type mice.
Ebolavirus NPC1 Role In Vivo
May/June 2015 Volume 6 Issue 3 e00565-15 ® mbio.asm.org 3
lighted the utility of 2-hydroxypropyl--cyclodextrin (HPBCD)
treatments for clearing cholesterol and glycosphingolipids from
late endosomal/lysosomal compartments, delaying onset of clini-
cal disease, and increasing longevity of NPC1- and NPC2-
deficient mice (30, 31). Leveraging these findings, we treated
Npc1/, Npc1/, and wild-type littermate controls with HP-
BCD every other day to clear cholesterol from late endosomal/
lysosomal compartments. HPBCD-treatedNpc1/ andNpc1/
mice had wild-type phenotypes with respect to late endosomal/
lysosomal cholesterol accumulation, as evidenced by filipin label-
ing in brain sections (Fig. 3C). HPBCD-treated Npc1/,
Npc1/, and wild-type littermate control mice were then ex-
posed i.p. to 100 PFU of mouse-adapted EBOV, and morbidity
and mortality were monitored. HPBCD-treated wild-type mice
succumbed to EBOV infection with expected clinical signs of dis-
ease (Fig. 3D and E). HPBCD-treated Npc1/mice were largely
protected from EBOV challenge and presented with similar clini-
cal signs of disease and mortality as those observed in untreated
Npc1/mice. As with untreatedNpc1/mice, HPBCD-treated
Npc1/ mice were completely protected from EBOV challenge
and did not display clinical signs of infection.
NPC1 inhibitors block filovirus replication in vitro. The am-
phipathic cationic amine U18666a, a known Niemann-Pick phe-
notype inducer, was previously shown to block filovirus entry and
replication in vitro (12). To determine if imipramine, another re-
ported inducer of the Niemann-Pick phenotype, is capable of in-
hibiting filovirus replication, we infected human umbilical vein
epithelial cells (HUVECs)withMARVor EBOV in the presence or
absence of imipramine at nontoxic levels (see Fig. S3 in the sup-
plemental material). Compared to control treated cells, imipra-
mine at 10 M significantly inhibited both MARV and EBOV
replication in HUVECs (Fig. 4A). We also evaluated the antiviral
activity of compound 3.47, which was previously shown to block
binding of EBOV GP to NPC1-containing membranes (13). Sur-
prisingly, while 20 M 3.47 strongly inhibited EBOV replication,
as previously reported, it had no significant antiviral activity
against MARV or SUDV in Vero cells (Fig. 4B). Consistent with
these findings, 3.47 potently inhibited EBOVGP-dependent entry
and infection by vesicular stomatitis virus (VSV) pseudotypes, but
it had little effect on viral entry mediated by SUDV, RESTV, or
MARV (Fig. 4C). Thus, U18666A and imipramine broadly inhibit
filovirus entry and infection, whereas 3.47 has a more narrow
spectrum of action.
Pharmacological induction of the NPC1 phenotype reduces
viral replication but does not provide significant protection
against filovirus infection in vivo. To test the in vivo efficacy of
the NPC1 GP-binding inhibitor 3.47, we completed dosing stud-
ies in which wild-type mice were exposed i.p. to 100 PFU of
mouse-adapted EBOV and treated daily with compound 3.47 at
various doses. Compared to vehicle control mice, compound 3.47
FIG 2 Serum cytokine levels following mouse-adapted EBOV infection of wild-type and NPC1 knockout mice. Npc1/, Npc1/, and wild-type littermate
control mice were challenged i.p. with 100 PFU of mouse-adapted EBOV. Serum collected at day 3 (A and C) or 7 (B and D) postchallenge was used to assess
cytokine levels in a BioPlex assay. °, P 0.05; °°, P 0.01; °°°, P 0.001; °°°°, P 0.0001 compared to uninfected control mice. *, P 0.05; **, P 0.01; ***,
P 0.001; ****, P 0.0001 compared to wild-type mice.
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did not result in a statistically significant increase in survival fol-
lowing EBOV challenge, as all mice in all dosage groups displayed
clinical signs of disease and succumbedby day 10 (see Fig. S4 in the
supplemental material). Due to solubility limitations, 25mg/kg of
body weight was the maximum dose attainable for compound
3.47.
To investigate the potential anti-EBOV efficacy of imipramine,
we challengedwild-typemice i.p. with 100 PFUofmouse-adapted
FIG 3 Cholesterol accumulation does not confer resistance to mouse-adapted EBOV infection. Npc2/ (n 9), Npc2/ (n 11), and wild-type littermate
control (n  10) mice were challenged i.p. with 100 PFU of mouse-adapted EBOV. Mice were monitored for weight loss (A) and mortality (B) following
challenge. Npc1/ (n 8), Npc1/ (n 11), and wild-type littermate control (n 11) mice were treated or not with HPBCD starting at 7 days of age and
continuing every other day until sacrifice at 7weeks of age (33 to 36 days old). (C) Filipin staining of unesterified cholesterol was evaluated in the dorsal neocortex
of HPBCD-treated and control mice. Cholesterol accumulation is seen as white areas, primarily cytoplasmic, examples of which are denoted by red arrows.
Images were taken at 20. Bar, 50 m. 2-Hydroxypropyl--cyclodextrin-treated mice were challenged i.p. with 100 PFU of mouse-adapted EBOV. Mice were
monitored for weight loss (D) and mortality (E) following challenge. ***, P 0.001; ****, P 0.0001 compared to wild-type mice.
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EBOV and treated mice i.p. daily (sid) or every other day (qod)
with imipramine at 20 mg/kg. The dose was based on published
reports of the in vivo activity of imipramine (32–36) and on pre-
liminary dosing studies completed by our group (data not
shown). Control mice were treated daily with an equal volume of
vehicle control i.p. Imipramine treatments did not significantly
reduce weight loss attributed to EBOV infection compared to
control mice, and daily imipramine treatments did not confer
significant protection (P 0.066) or delay to death (P 0.067)
compared to vehicle-treated control mice (Fig. 5A and B).
However, in tissues collected from a subset of mice on days 3
and 5 postchallenge, imipramine treatment did significantly
reduce viral titers compared to those in vehicle-treated control
mice (Fig. 5C and D).
We next tested the in vivo efficacy of U18666a. Here, we chal-
lenged mice i.p. with 100 PFU of mouse-adapted EBOV and
treated mice daily, i.p., with U18666a at 2 mg/kg. As with imipra-
mine, the dose was based on the reported in vivo activity of
U18666a (37, 38) and results of preliminary studies completed by
our group (data not shown). Control mice were treated daily with
an equal volume of vehicle control by i.p. injection. Daily treat-
ments with U18666a did not reduce EBOV-induced weight loss,
nor did they provide increased protection from mouse-adapted
EBOV challenge compared to control treated mice (Fig. 6A and
B). Much like imipramine, U18666a treatments did reduce viral
titers in serum, liver, and spleen, but only on day 3 postchallenge
(Fig. 6C and D). While imipramine and U18666a provided only
modest protection against EBOV morbidity, these compounds
did significantly reduce viral replication in vivo. These data suggest
that NPC1-targeting therapeutics, with enhanced NPC1 specific-
ity and a greater capacity to reduce viral load, could augment
survival after EBOV infection.
DISCUSSION
The importance of NPC1 for filovirus entry into host cells has
been clearly shown in previous work (12, 13, 39, 40). In addition,
Npc1/mice were reported to have a strong survival advantage,
relative to wild-typemice when exposed tomouse-adapted EBOV
or MARV; however, these mice did display clinical symptoms of
filovirus infection (12). Here we show, for the first time, that
Npc1/ mice are completely resistant to mouse-adapted EBOV
infection, with no apparent clinical signs of EBOV infection
(Fig. 1). Strikingly, no detectable viral titers were observed in tis-
sues collected fromEBOV-challengedNpc1/mice (Fig. 1). Fur-
thermore, histological analysis illustrated no virus-induced le-
sions in liver and spleen tissue, and both tissues were negative for
viral antigen by immunohistochemistry staining (see Fig. S1 and
S2 in the supplemental material). This is the first evidence that
complete loss of NPC1 expression in vivo results in absolute resis-
tance to filovirus replication and pathogenesis. We therefore con-
clude that NPC1 is a bona fide target for therapeutics aimed at the
prevention and control of filovirus infections.
In contrast to the findings with theNpc1/mice, we observed
high levels of viral replication andweight loss in EBOV-challenged
Npc1/mice (Fig. 1). Interestingly, however, and consistent with
the resistance of theNPC1 heterozygotes to EBOV challenge, both
viral titers and clinical signs observed inNpc1/micewere short-
lived in comparison to those observed in wild-type mice (Fig. 1).
The elevated levels of IL-5 and IL-12 at day 7 postinfection (Fig. 2)
in Npc1/ mice and not in wild-type mice strongly suggest that
FIG 4 Imipramine and compound 3.47 inhibit filovirus replication and
GP-mediated entry in vitro. Filovirus infected HUVEC and Vero cells were
treated with or without imipramine (A) or compound 3.47 (B), respectively.
Cells were fixed at 48 or 72 h postinfection, and infected cells were enumerated
using MARV-, EBOV-, or SUDV-specific monoclonal antibodies and a fluo-
rescently labeled secondary antibody. (C) Vero cells were treated with com-
pound 3.47 at the indicated concentrations prior to infection with GFP-
expressing VSV pseudoviruses. Cells were fixed 16 to 24 h postinfection, and
infected cells were assessed by eGFP expression analysis. *, P 0.05; ***, P
0.001.
Herbert et al.
6 ® mbio.asm.org May/June 2015 Volume 6 Issue 3 e00565-15
adaptive immune responses, particularly B cell responses, were
elicited only in the heterozygotes, a finding that may explain the
difference in survival and viral titers between these two groups.
Furthermore, proinflammatory cytokines MIP-1, MCP-1, and
RANTES remained elevated in wild-type mice at day 7 postinfec-
tion (Fig. 2), when these cytokines are normally downregulated.
This unchecked proinflammatory state is a hallmark of EBOV
infection, yet Npc1/mice seem to more appropriately regulate
both innate and adaptive immune responses than their wild-type
counterparts, despite having equivalent viral titers at day 3 postin-
fection (Fig. 1). While the mechanism for this differential regula-
tion of the proinflammatory immune response betweenwild-type
andNpc1/mice remains to be fully elucidated, these findings do
suggest that complete loss of NPC1 expression or function is not
required for survival. Instead, simply lowering NPC1 expression
below a yet-to-be defined threshold may be sufficient to provide
protectionwhenusingNPC1-targeted filovirus therapeutics. Such
a possibility also raises the question of whether the partial resis-
tance in Npc1/ mice could be reflective of a heterozygote ad-
vantage in humans exposed to EBOV. While controversial, such
conjectures have been made for another lysosomal disease and
infectious agent, namely, that of Tay-Sachs disease heterozygosity
providing protection against infection byMycobacterium tubercu-
losis (41).
Niemann-Pick type C disease caused by abnormality in NPC1
or NPC2 function leads to accumulation of cholesterol and glyco-
sphingolipids in late endosomes (19, 42, 43), the presumed site of
filovirus membrane fusion and cytoplasmic escape (44, 45). This
raises the possibility that stored lysosomal cholesterol and glyco-
sphingolipids (or their effects on cellular physiology) may inhibit
filovirus entry. Carette, Cote, and colleagues previously demon-
strated that NPC2-deficient fibroblasts were susceptible to filovi-
rus GP-mediated entry (12, 13), suggesting that late endosomal
cholesterol/glycosphingolipid accumulation alone is insufficient
to block filovirus entry. Here, we found that NPC2 knockoutmice
were as susceptible to mouse-adapted EBOV as wild-type mice
(Fig. 3), even though these knockout mice have a similar choles-
terol/glycosphingolipid accumulation phenotype as filovirus-
resistant NPC1 knockout mice (46). Yet, this does not directly
address whether the buildup of cholesterol or glycosphingolipids
in late endosomes of NPC1-deficient cells contributes to resis-
tance against filovirus infection. To answer this question, we
FIG 5 Imipramine reduces EBOV replication in vivo. Wild-type mice were challenged i.p. with 100 PFU of mouse-adapted EBOV and treated either sid (n
39) or qod (n 30) with 20 mg/kg of imipramine. Control mice (n 40) received an equivalent volume of vehicle control sid. Mice were monitored for weight
loss (A) and mortality (B) following challenge. On days 3 (C) and 5 (D) postchallenge, subsets of mice from control and qod groups were euthanized, and viral
titers were determined for the indicated tissues by plaque assay. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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treated NPC1 knockout mice with HPBCD, which successfully
cleared cholesterol from the late endosomes of thesemice (Fig. 3).
Despite the restoration of normal cellular cholesterol levels in
these mice, they remained completely resistant to mouse-adapted
EBOV challenge (Fig. 3). The converse is true as well. Cote et al.
reported that CHO cells expressing NPC1mutant P692S were still
susceptible to EBOV-GP pseudovirus infection despite having a
cholesterol trafficking defect that resulted in aNiemann-Pick type
C phenotype (13). These findings provide further evidence that
the lack of NPC1 in NPC1-deficient cells or mice is solely respon-
sible for filovirus resistance, with little or no role for late endo-
somal cholesterol or glycosphingolipid accumulation.
Class 2 amphiphiles U18666a and imipramine are known to
interfere with intracellular cholesterol trafficking, possibly
through antagonizing NPC1 function, though the mechanism is
not well understood (47). Cells treated with either U18666a or
imipramine accumulate cholesterol and glycosphingolipids in late
endosomes in much the same way NPC1- or NPC2-deficient cells
do (26–28). Carette et al. demonstrated that treating cells with
U18666a severely limited filovirus replication (12); however, the
antifilovirus activity of U18666a did not seem to be a result of
direct inhibition of GP-NPC1 binding (13). Here, we have illus-
trated a similar antiviral activity of imipramine against filovirus
using physiologically relevant HUVECs (Fig. 4), which is in agree-
ment with previously reported antiviral activity in VSV pseudovi-
rus assays (12) and authentic EBOV infection in HeLa cells (48).
Compound 3.47 has previously been shown to inhibit EBOV GP-
mediated entry of VSV pseudotypes by blocking GP-NPC1 bind-
ing (13).We determined that compound 3.47 was efficient at lim-
iting EBOV infection in vitro but that the antiviral effect seemed to
be limited to EBOV (Fig. 4). Compound 3.47 had little or no
antiviral effect against MARV or SUDV, suggesting a mechanistic
difference betweenMARV and SUDVGP engagement withNPC1
compared to that of EBOVGP. This is somewhat surprising, given
that presumptive NPC1-binding sequences in the GP1 head sub-
domain are highly conserved among ebolaviruses (marburgvi-
ruses are more divergent) (49). Moreover, infection by EBOV,
MARV, or SUDV requires the same loop C region of NPC1 (39).
Uncovering the molecular basis of the GP-loop C binding inter-
action and delineating GP strain-dependent differences in this
interaction may help explain the filovirus species selectivity of
3.47.
NPC1 represents a promising target for the development of
filovirus therapeutics. Given the in vitro efficacy ofU18666a, imip-
FIG 6 U18666a reduces EBOV replication in vivo. Wild-type mice were challenged i.p. with 100 PFU of mouse-adapted EBOV and treated sid with either
2mg/kg ofU18666a (n 39) or an equivalent volume of vehicle control (n 38).Miceweremonitored forweight loss (A) andmortality (B) following challenge.
On days 3 (C) and 5 (D) postchallenge, subsets of mice from each group were euthanized and viral titers were determined for indicated tissues by plaque assay.
*, P 0.05; **, P 0.01.
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ramine, and compound3.47,we chose to investigate the therapeu-
tic potential of these compounds by using a mouse model of
EBOV disease. We were unable to provide protection to EBOV-
infected mice with compound 3.47 (see Fig. S4 in the supplemen-
tal material), even when we treated themwith the maximal allow-
able dose, dictated by solubility limitations. As forU18666a, lower
doses seemed to be better tolerated and more efficacious against
EBOV infection, though at no dose of U18666a was there a statis-
tically significant enhancement in survival compared to control
mice (Fig. 6). Lower doses of imipramine also seemed to be more
protective against EBOV infection (Fig. 5). Imipramine treatment
afforded a moderate increase in survival that approached statisti-
cal significance (P  0.066), and both U18666a and imipramine
treatment did significantly reduce viral replication in liver, spleen,
and serumcompared to controlmice (Fig. 5 and 6).Other cationic
amphiphiles reported to induce an NPC1-deficient phenotype
have also demonstrated potent antiviral activity against Ebolavi-
rus replication in cells (50), though no direct perturbance of GP-
NPC1 binding could be established. In addition to in vitro antivi-
ral activity, preliminary mouse studies suggest that two of these
cationic amphiphiles, clomiphene and toremifene, can provide
protection against EBOV infection (51). Collectively, these data
suggest that therapies targeting the NPC1 pathway, either directly
or indirectly, can effectively limit filovirus replication and that
therapies more efficient at blocking NPC1-GP bindingmay prove
to be potent antifilovirus therapies. In the case of cationic am-
phiphiles, the lack of a mechanistic understanding makes it diffi-
cult to decipher why exactly these compounds are more or less
effective. One possible explanation is their limited NPC1 specific-
ity, which may result in only reduced, yet sufficient, NPC1 avail-
ability for filovirus engagement (27, 52, 53). Alternatively, these
compounds may be hindered by pharmacokinetic limitations
such that therapeutic concentrations may not be without adverse
side effects. Developing NPC1-directed therapies that limit filovi-
rus replication and pathogenesis more efficiently than U18666a
and imipramine may tip the balance in favor of the immune sys-
tem, allowing the host to clear the virus and survive.
MATERIALS AND METHODS
Cells and viruses.Vero E6 cells (ATCC) were maintained in Eagle’s min-
imal essential medium (EMEM) supplemented with 5% heat-inactivated
fetal bovine serum (FBS) and gentamicin (50 g/ml) at 37°C, 5% CO2,
and 80%humidity. HUVECs (ATCC)weremaintained in endothelial cell
Basal Medium-2 (Lonza) supplemented with 5% FBS and penicillin-
streptomycin (100 U; 100 g/ml) at 37°C, 5% CO2, and 80% humidity.
SUDV Boniface, EBOV Kikwit, and MARV Ci67 viruses were used for all
in vitro experiments. Mouse-adapted EBOV was used for all mouse chal-
lenge studies (54). VSV pseudotypes bearing glycoproteins derived from
VSV, EBOV, SUDV, RESTV, and MARV were generated as described
previously (55).
Drugs and compounds. Imipramine-HCl stock (catalog number
I7379; Sigma-Aldrich) used for both in vitro and in vivo studies was re-
constituted in sterile 0.9% sodium chloride solution (0409-4888; Hos-
pira) at 50 mg/ml and stored at room temperature. Imipramine working
stocks used for in vitro studieswere diluted at the indicated concentrations
in appropriate culturemedia. Imipramineworking stocks used for daily in
vivo treatments were diluted to appropriate concentrations in sterile 0.9%
sodium chloride solution. U18666a stock (U3633; Sigma-Aldrich) was
reconstituted in sterile water at 10 mg/ml and stored at 4°C. U18666a
working stocks used for daily in vivo treatments were diluted to appropri-
ate concentrations in sterile phosphate-buffered saline (PBS). 3.47 stock
(MBX2545; Microbiotix) used for in vitro studies was reconstituted in
dimethyl sulfoxide (DMSO) at 20 mM and stored at 20°C. 3.47 stock
used for in vivo studies was reconstituted in sterile 20% HPBCD solution
(H107; Sigma-Aldrich) at 5 mg/ml and stored at 4°C. 3.47 working stocks
used for daily in vivo treatments were diluted to appropriate concentra-
tions in sterile 40% HPBCD solution.
In vitro infection of Vero cells and HUVECs. Vero E6 cells or HU-
VECs were seeded in 96-well poly-D-lysine-coated black plates (Greiner
Bio-OneCellcoat) at 5 104 cells per well in culture medium. Cells were
pretreated with culture medium containing imipramine (10 M), 3.47
(20 M), or culture medium alone for 1 h at 37°C, 5% CO2, and 80%
humidity prior to infectionwithMARV, EBOV, or SUDVat amultiplicity
of infection of 1. Following a 1-h incubation with virus at 37°C, 5% CO2,
and 80% humidity, fresh culture medium with or without imipramine
(10 M) or 3.47 (20 M) was added to the cells. Uninfected cells with or
without imipramine (10M)or 3.47 (20M) served as negative controls.
Cells were incubated at 37°C, 5% CO2, and 80% humidity and subse-
quently fixed with 10% formalin at 48 and 72 h postinfection. Infectivities
of VSV pseudotypes in Vero cells were measured by manually counting
enhanced green fluorescent protein (eGFP)-positive cells using fluores-
cencemicroscopy at 16 to 24 h postinfection, as described previously (44).
Immunofluorescence assay. For the immunofluorescence assays,
formalin-fixed cells were blockedwith 1%bovine serumalbumin solution
prior to incubation with primary antibodies. MARV-, EBOV-, or SUDV-
infected cells and uninfected control cells were incubated with MARV-
specificmurinemonoclonal antibody 9G4, EBOV-specific humanmono-
clonal antibody KZ52, or SUDV-specific murine monoclonal antibody
3C10, respectively. Cells were washed with PBS prior to incubation with
either goat anti-mouse IgG–Alexa Fluor 488 or goat anti-human IgG–
Alexa Fluor 488 (Molecular Probes). Cells were stainedwithHoechst stain
(Molecular Probes) and then washed with PBS and stored at 4°C. Images
were acquired at 9 fields/well with a 10 objective lens on a Discovery-1
high-content imager (Molecular Devices) or at 6 fields/well with a 20
objective lens on an Operetta (PerkinElmer) high-content device.
Discovery-1 images were analyzedwith the “live/dead”module inMetaX-
press software. Operetta images were analyzed with a customized scheme
built from image analysis functions present inHarmony software, and the
percentage of infected cells was determined using the analysis functions.
Cholesterol was visualized using 0.005% filipin complex (F9765;
Sigma-Aldrich) diluted in DMSO, and staining was carried out as previ-
ously described (56). Briefly, 4% paraformaldehyde-fixed hemicoronal
sections were cut at 35-m thickness on a Leica VT1000S Vibratome.
Sections were washed two times for 10 min in PBS, then two times for
10 min in 0.02% saponin (S7900; Sigma-Aldrich)–PBS (wash solution),
and incubated with DMSO-PBS (control) or filipin complex-PBS for
20 min at room temperature. Sections were then washed two times for
10 min in wash solution and finally two times for 10 min in PBS. Tissue
sections were mounted on slides, and coverslips were attached using Pro-
Long Gold Antifade mounting medium (P36930; Life Technologies).
In vivo challenge studies. Animal research was conducted in compli-
ance with the Animal Welfare Act and other federal statutes and regula-
tions relating to animals and experiments involving animals and adhered
to the principles stated in the Guide for the Care and Use of Laboratory
Animals of theNational ResearchCouncil (57). The facility is fully accred-
ited by the Association for the Assessment and Accreditation of Labora-
tory Animal Care International, All challenge studies were conducted un-
der maximum containment in an animal biosafety level 4 (BSL-4) facility
at USAMRIID and were approved by the USAMRIID Institutional Ani-
mal Care and Use Committee under protocols AP-10-004, AP-10-005,
and AP-11-004.
Npc1 and Npc2 heterozygous and homozygous knockout mice
(BALB/c background) andwild-type littermates were bred and genotyped
at Albert Einstein College of Medicine, as described previously (30), and
subsequently shipped to USAMRIID at 3 to 5 weeks of age. Wild-type
BALB/c mice used for drug efficacy studies were purchased from the Na-
tional Cancer Institute, Frederick, MD.
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For knockout studies, 3- to 5-week-old Npc1 or Npc2 heterozygous
and homozygous knockout mice and wild-type littermates were chal-
lenged i.p. with a target dose of 100 PFU ofmouse-adapted EBOV diluted
in 200 l of PBS. Mice were monitored for morbidity and mortality, and
weight loss was recorded. On days 3 and 7 postchallenge, a subset of
Npc1/,Npc1/, and wild-typemice were euthanized to collect serum,
liver, spleen, and kidney tissue for virus titer determinations. Npc1/,
Npc1/, andwild-type control animals that receivedHPBCD treatments
were injected subcutaneously with 20% HPBCD solution (Sigma-
Aldrich) at 4,000 mg/kg every other day starting at postnatal day 7 (P7)
until the end of the challenge study or death of the animal (30). Titration
of challenge inocula determined that the mice received between 92.5 and
135 PFU of mouse-adapted EBOV.
For drug efficacy studies, 8- to 10-week-old female wild-type BALB/c
mice were challenged i.p. with a target dose of 100 PFU ofmouse-adapted
EBOV diluted in 200 l of PBS. Thirty minutes postchallenge, mice were
treated i.p. with imipramine, U18666a, or 3.47 at the indicated concen-
trations in 100 to 200 l of diluent. Control mice for each experiment
received an equal volume of appropriate vehicle control. Treatments con-
tinued daily or every other day as on day 0, until day 10 postinfection.
Where indicated, a subset of mice from treatment groups and control
groups were euthanized on days 3 and 5 postinfection to collect serum,
liver, and spleen tissue for viral titer determinations. Titration of challenge
inocula determined that the mice received between 92.25 and 110 PFU of
mouse-adapted EBOV.
Plaque assay for viral titers. For plaque assays to determine viral ti-
ters, tissues were weighed and 10% tissue homogenates were generated in
RPMI supplemented with 2% FBS using a gentleMACS dissociator
(Miltenyi Biotec). Ten-fold serial dilutions of tissue homogenates or se-
rum were prepared in modified Eagle’s medium with Earle’s balanced
salts and nonessential amino acids (EMEM/NEAA) supplemented with
5% FBS, 2 mM L-glutamine, and 1% gentamicin. Aliquots (200 l) of
each dilution were inoculated onto 6-well plates of confluent monolayers
of Vero E6 cells. After adsorption for 1 h at 37°C, 5% CO2, and 80%
humidity, monolayers were overlaid with a mixture of 1 part 1% agarose
(SeaKem) and 1 part 2 Eagle basal medium (EBME), 30 mM HEPES
buffer, and 5% FBS. After incubation at 37°C, 5% CO2, and 80% hu-
midity for 6 days, a secondoverlaywith 5%neutral redwas added. Plaques
were counted the following day, and titers are reported as PFU per milli-
liter of the 10% tissue homogenates.
Pathology. The liver, spleen, and kidney were collected at the indi-
cated days postinfection and fixed in formalin for histopathology and
immunohistochemistry. Each formalin-fixed tissue sample was trimmed
and embedded in paraffin. Sections of the paraffin-embedded tissues,
5 m thick, were cut for histology. The histology slides were deparaf-
finized, placed on coverslips, and stained with hematoxylin and eosin
(H&E).
Immunohistochemistry was performed on all tissue sections by using
the UltraVision (mouse on mouse) HRP kit. A mouse monoclonal anti-
EBOV antibody (702/703) was used at a dilution of 1:8,000. After depar-
affinization and methanol and H2O2 blocking, sections were pretreated
with proteinase K (Dako) at room temperature for 6 min. Sections were
rinsed with PBS and then covered with serum-free protein block (Dako)
plus 10% normal goat serum for 30 min. A rodent block was then applied
for 45 min, followed by primary antibody for 30 min. The sections were
then rinsed, and peroxidase-labeled polymer (secondary antibody) was
applied for 30 min. Slides were rinsed, and a substrate-chromogen solu-
tion was applied for 5 min. The substrate-chromogen solution was rinsed
off the slides, and slides were stained with H&E and rinsed. The sections
were dehydrated, cleared with Xyless, and then placed on coverslips. The
intensity of EBOV antigen labeling was semiquantitatively documented
using a scale of 1 to 4, with 4 representing the highest concentration of
antigen labeling (0, no cells in section were EBOV positive; 1, 10% of
cells in section were positive [minimal]; 2, 11 to 25% of cells in section
were positive [mild]; 3, 26 to 50% of cells in section were positive [mod-
erate]; 4.50% of cells in section were positive [marked]).
BioPlex assay for cytokine analysis. For the BioPlex assay (Bio-Rad
Laboratories, Inc.), serum was collected from Npc1 homozygous and
heterozygous knockoutmice andwild-type littermate controls on day 3 or
7 postinfection with mouse-adapted EBOV. Cytokine concentrations
were evaluated in accordance with the manufacturer’s instructions. Se-
rum cytokine levels for each respective cytokine were quantitated using
defined standard curves optimized for serum product.
Statistical analysis. Survival curves were analyzed using the Fisher’s
exact test (two tailed) with a step-down Bonferroni adjustment for sur-
vival rate comparisons. Time-to-death comparisons were completed us-
ing the t test with Dunnett’s correction. All cytokine and tissue titration
data were analyzed via group comparisons using linear regression of the
response variable with the main effects for day and group interactions.
Cytokine variables were untransformed, while all the titer variables were
based on log10 transformations.
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